Medpace Holdings, Inc. (NASDAQ:MEDP)‘s stock had its “hold” rating restated by equities researchers at KeyCorp in a report released on Tuesday.

Several other equities analysts also recently commented on MEDP. Robert W. Baird reiterated a “hold” rating and set a $32.00 price target on shares of Medpace Holdings in a report on Monday, October 9th. Raymond James Financial, Inc. began coverage on shares of Medpace Holdings in a report on Friday, September 29th. They set a “market perform” rating on the stock. Zacks Investment Research upgraded shares of Medpace Holdings from a “hold” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a report on Saturday, September 9th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $31.00 price target (up from $30.00) on shares of Medpace Holdings in a report on Wednesday, August 2nd. Six research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $34.20.

Medpace Holdings (NASDAQ MEDP) traded up 0.18% during mid-day trading on Tuesday, hitting $33.49. The company had a trading volume of 17,515 shares. Medpace Holdings has a 1-year low of $21.76 and a 1-year high of $38.94. The stock has a market capitalization of $1.32 billion, a PE ratio of 58.96 and a beta of -0.86. The stock has a 50 day moving average price of $32.41 and a 200-day moving average price of $29.69.

Medpace Holdings (NASDAQ:MEDP) last announced its earnings results on Monday, July 31st. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.08. The firm had revenue of $94.60 million for the quarter, compared to analysts’ expectations of $92.71 million. Medpace Holdings had a net margin of 5.37% and a return on equity of 9.32%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 EPS. On average, analysts forecast that Medpace Holdings will post $1.43 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “KeyCorp Reiterates “Hold” Rating for Medpace Holdings, Inc. (MEDP)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/19/keycorp-reiterates-hold-rating-for-medpace-holdings-inc-medp.html.

In related news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total transaction of $60,540,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 25.80% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. American International Group Inc. bought a new position in Medpace Holdings in the 1st quarter worth about $145,000. Tudor Investment Corp ET AL grew its stake in Medpace Holdings by 16.4% in the 1st quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock worth $205,000 after acquiring an additional 967 shares in the last quarter. Susquehanna International Group LLP bought a new position in Medpace Holdings in the 2nd quarter worth about $220,000. Credit Suisse AG bought a new position in Medpace Holdings in the 1st quarter worth about $231,000. Finally, Rhumbline Advisers grew its stake in Medpace Holdings by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 9,726 shares of the company’s stock worth $282,000 after acquiring an additional 1,140 shares in the last quarter. Institutional investors own 15.97% of the company’s stock.

About Medpace Holdings

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Analyst Recommendations for Medpace Holdings (NASDAQ:MEDP)

Receive News & Stock Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related stocks with our FREE daily email newsletter.